See more : Kintor Pharmaceutical Limited (9939.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Zhongchao Inc. (ZCMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhongchao Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Aprogen Medicines Inc. (007460.KS) Income Statement Analysis – Financial Results
- China Reinsurance (Group) Corporation (1508.HK) Income Statement Analysis – Financial Results
- Honey Badger Silver Inc. (TUF.V) Income Statement Analysis – Financial Results
- Ambu A/S (AMBFF) Income Statement Analysis – Financial Results
- Shinyei Kaisha (3004.T) Income Statement Analysis – Financial Results
Zhongchao Inc. (ZCMD)
About Zhongchao Inc.
Zhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. It also provides customized medical courses and medical training services; and patient management services through online platform under the Zhongxun brand. The company operates through its mdmooc.org online platform under the MDMOOC brand; and Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 19.43M | 14.15M | 16.30M | 17.99M | 14.88M | 12.87M | 9.82M |
| Cost of Revenue | 10.92M | 7.79M | 6.86M | 6.12M | 4.66M | 4.46M | 3.97M |
| Gross Profit | 8.51M | 6.36M | 9.44M | 11.87M | 10.23M | 8.41M | 5.85M |
| Gross Profit Ratio | 43.80% | 44.92% | 57.92% | 65.99% | 68.72% | 65.36% | 59.56% |
| Research & Development | 514.41K | 411.52K | 758.88K | 816.55K | 864.32K | 1.45M | 943.25K |
| General & Administrative | 6.70M | 6.80M | 5.86M | 3.12M | 2.52M | 1.43M | 1.14M |
| Selling & Marketing | 6.71M | 2.10M | 3.14M | 3.44M | 3.20M | 2.26M | 2.72M |
| SG&A | 13.41M | 8.90M | 9.00M | 6.57M | 5.72M | 3.69M | 3.85M |
| Other Expenses | 7.87M | 262.44K | 34.00K | 305.57K | 534.02K | 37.36K | 275.02K |
| Operating Expenses | 21.80M | 9.31M | 9.76M | 7.38M | 6.58M | 5.13M | 4.80M |
| Cost & Expenses | 32.72M | 17.11M | 16.62M | 13.50M | 11.24M | 9.59M | 8.77M |
| Interest Income | 237.05K | 142.01K | 175.99K | 146.97K | 211.48K | 191.61K | 17.33K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 923.61K | 730.31K | 679.79K | 403.01K | 240.51K | 28.78K | 16.27K |
| EBITDA | -4.90M | -2.22M | 382.24K | 4.49M | 3.64M | 3.30M | 1.06M |
| EBITDA Ratio | -25.23% | -15.72% | 2.35% | 27.32% | 26.23% | 25.75% | 10.85% |
| Operating Income | -13.28M | -2.95M | -320.74K | 4.49M | 3.64M | 3.27M | 1.05M |
| Operating Income Ratio | -68.35% | -20.88% | -1.97% | 24.96% | 24.47% | 25.45% | 10.68% |
| Total Other Income/Expenses | 1.31M | 404.46K | 209.99K | 452.53K | 745.50K | 228.97K | 292.35K |
| Income Before Tax | -11.98M | -2.55M | -110.75K | 4.94M | 4.39M | 3.50M | 1.34M |
| Income Before Tax Ratio | -61.63% | -18.02% | -0.68% | 27.47% | 29.48% | 27.23% | 13.66% |
| Income Tax Expense | -669.76K | 272.31K | -349.42K | 484.79K | 387.14K | 502.13K | -153.95K |
| Net Income | -11.34M | -2.82M | 238.67K | 4.46M | 4.05M | 3.02M | 1.53M |
| Net Income Ratio | -58.33% | -19.94% | 1.46% | 24.78% | 27.19% | 23.47% | 15.58% |
| EPS | -4.35 | -1.09 | 0.10 | 1.83 | 1.87 | 1.45 | 0.78 |
| EPS Diluted | -4.35 | -1.09 | 0.10 | 1.83 | 1.87 | 1.45 | 0.78 |
| Weighted Avg Shares Out | 2.60M | 2.60M | 2.49M | 2.44M | 2.16M | 2.08M | 1.96M |
| Weighted Avg Shares Out (Dil) | 2.60M | 2.60M | 2.49M | 2.44M | 2.16M | 2.08M | 1.96M |
Zhongchao Inc. Partners with Ximalaya to Launch the First Audio Course Series for Cancer Education
Penny Stocks To Buy Now? 5 To Watch After News This Week
Zhongchao Inc. Launches Hematology MDT Training Platform to Improve Diagnosis and Treatment
Zhongchao Inc. Announces Hematological Tumor Patient Management Business to Further Expand to Out-of-Hospital Market
Zhongchao Inc. Expands Patient Management Business to Ovarian Cancer Market
Zhongchao Inc. Builds A Patient DOT Management System
Zhongchao Inc. Builds A Platform for Breast Cancer Tiered Diagnosis and Treatment Improvement To Promote the Equalization of Breast Cancer Diagnosis and Treatment Level
Zhongchao Inc. Announces the Establishment of a New Subsidiary Ningxia Zhongxin Internet Hospital Co., Ltd. for Patient Management
Zhongchao: Cheap Growth And Value Healthcare Education Stock
Zhongchao Inc. Partners with a Subsidiary of AbbVie Inc. (NYSE: ABBV) for Medical Education Services
Source: https://incomestatements.info
Category: Stock Reports